Predictive Oncology Launches Website Highlighting AI-Powered Cancer Research Advancements
The website features information about
“The website redesign is really intended to showcase the great work that all these teams have been doing, and emphasize what they’re all contributing to the same grand mission under the
Here’s a closer look at each of Predictive Oncology’s subsidiaries and how they’re contributing to advancing cancer research and saving lives:
Helomics: Helomicsmaintains a database that includes information on 137 types of tumors and more than 15 years of treatment outcome data spanning more than 150,000 clinical cases. Helomicsrelies on proprietary artificial intelligence software, known as the Computational Research Engine (CoRE™), to analyze this rich set of data and personalize cancer therapies for patients. It can also help drive the development of new targeted therapies in collaborations with pharmaceutical companies, finding effective treatments more quickly and helping them get to clinical trials.
- Soluble Biotech: Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes. Soluble Biotech can help decrease the cost, time, and demand on resources conventionally needed to optimize formulations, cutting the average time down from one year to just three months.
- TumorGenesis: TumorGenesis enables researchers to better study cancer cells found in tumors of the blood and all organ systems. TumorGenesis achieves this by growing cancer cells in the lab while retaining the unique DNA/RNA and proteomic signatures that would exist inside a patient’s body. In this way, TumorGenesis offers a granular view of the tumor -- and the information needed to effectively treat the patient’s cancer. Currently, TumorGenesis is focused on studying ovarian cancer tumors, covering 25 ovarian cancer cell lines representing 90% of ovarian cancers.
“Eliminating cancer may seem like a lofty goal, and indeed such a complex disease isn’t going to be cured overnight,” said Engle. “But, with modern technology and the power of artificial intelligence, we have at our disposal some of the most potent tools to solve the challenges facing us in cancer research. Now that we can contextualize and cross-reference hundreds of thousands of case studies against detailed information about each and every tumor we have received, we can ensure our treatments are tailor-made to be most effective for each and every patient.”
As the drug discovery community realizes, a genomics-based approach to cancer research and drug development is insufficient to achieve the promise of personalized therapeutics.
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the
Investor Relations Contact:
Source: Predictive Oncology Inc.